BioSpace News Archive

Cosmetic dentistry refers to any work related to dental that changes and improves the look of a person’s gums and/or bite, teeth.

Critical and chronic care products are the branch of medicine concerned with the diagnosis and management of life-threatening conditions requiring sophisticated organ support and invasive monitoring whereas chronic care products refers to medical care products which addresses pre-existing or long term illness, as opposed to acute care which is concerned with diagnosis and treatment of short term or severe illness of brief duration.

The HIV/AIDS monitoring test deals with post-HIV detection to assess plasma status and immune function of HIV-infected patients.

Impetigo also known as impetigo contagiosa or pyoderma, is a bacterial skin infection highly contagious in nature.

Molecular imaging is a breakthrough technology that was introduced to the medical diagnostics world in the early 21st century.

Mycobacteria is a large bacterial group, precisely a genus of actinobacteria, cause infections in humans.

Oxford Biomedica plc, a leading gene and cell therapy group, and Homology Medicines, Inc., a genetic medicines company, announced that the companies have agreed to establish a high-performing, full scope Adeno-Associated Virus Manufacturing and Innovation Business in the U.S.

Royal Philips, a global leader in health technology, and the University Hospital Brandenburg an der Havel have signed a 10-year strategic partnership to renew and expand the hospital’s diagnostic and therapy options through the delivery of advanced technology solutions.

Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company is pleased to announce that it has received a Notice of Allowance from the Canadian Patent Office for patent application No. 3101853 entitled: Compositions and Methods for Treating Idiopathic Pulmonary Fibrosis.

Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) today announced updates on the Phase 3 development program for OLUMIANT ® (baricitinib) in adults with active systemic lupus erythematosus (also referred to as SLE and lupus) and the status of the U.S. atopic dermatitis supplemental new drug application (sNDA).